233 related articles for article (PubMed ID: 38397167)
1. Cardiac and Nephrological Complications Related to the Use of Antiangiogenic and Anti-Programmed Cell Death Protein 1 Receptor/Programmed Cell Death Protein 1 Ligand Therapy.
Stachyra-Strawa P; Szatkowska-Sieczek L; Cisek P; Gołębiowski P; Grzybowska-Szatkowska L
Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397167
[TBL] [Abstract][Full Text] [Related]
2. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kondo T; Shinohara N; Nonomura N; Ozono S; Eto M; Tatsugami K; Takayama T; Matsuyama H; Kishida T; Oya M;
Cancer Sci; 2019 Jun; 110(6):1820-1828. PubMed ID: 30972888
[TBL] [Abstract][Full Text] [Related]
4. [Nephrotoxicity of anti-angiogenesis drugs].
Grechukhina KS; Chebotareva NV; Krasnova TN
Ter Arkh; 2020 Jul; 92(6):93-98. PubMed ID: 33346501
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
6. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.
Nadal R; Amin A; Geynisman DM; Voss MH; Weinstock M; Doyle J; Zhang Z; Viudez A; Plimack ER; McDermott DF; Motzer R; Rini B; Hammers HJ
Ann Oncol; 2016 Jul; 27(7):1304-11. PubMed ID: 27059553
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition.
Hofmann I; Baum A; Hofmann MH; Trapani F; Reichel-Voda C; Ehrensperger D; Aichinger M; Ebner F; Budano N; Schweifer N; Sykora M; Depla E; Boucneau J; Gschwind A; Kraut N; Hilberg F; Künkele KP
J Pharmacol Exp Ther; 2023 Mar; 384(3):331-342. PubMed ID: 36241203
[TBL] [Abstract][Full Text] [Related]
8. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
[TBL] [Abstract][Full Text] [Related]
9. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).
Cosmai L; Gallieni M; Liguigli W; Porta C
J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025
[TBL] [Abstract][Full Text] [Related]
10. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
Front Immunol; 2020; 11():624547. PubMed ID: 33552089
[TBL] [Abstract][Full Text] [Related]
11. [Renovascular effects of antiangiogenic drugs].
Deray G; Janus N; Aloy B; Launay-Vacher V
Bull Cancer; 2016; 103(7-8):662-6. PubMed ID: 27318610
[TBL] [Abstract][Full Text] [Related]
12. Kidney injury during VEGF inhibitor therapy.
den Deurwaarder ES; Desar IM; Steenbergen EJ; Mulders PF; Wetzels JF; van Herpen CM
Neth J Med; 2012 Aug; 70(6):267-71. PubMed ID: 22859418
[TBL] [Abstract][Full Text] [Related]
13. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Launay-Vacher V; Deray G
Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
[TBL] [Abstract][Full Text] [Related]
14. Current Trends in Anti-Cancer Molecular Targeted Therapies: Renal Complications and Their Histological Features.
Tonooka A; Ohashi R
J Nippon Med Sch; 2022 May; 89(2):128-138. PubMed ID: 34840210
[TBL] [Abstract][Full Text] [Related]
15. Use of Antihypertensive Drugs in Neoplastic Patients.
Rizzoni D; De Ciuceis C; Porteri E; Agabiti-Rosei C; Agabiti-Rosei E
High Blood Press Cardiovasc Prev; 2017 Jun; 24(2):127-132. PubMed ID: 28361339
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
Izzedine H; Rixe O; Billemont B; Baumelou A; Deray G
Am J Kidney Dis; 2007 Aug; 50(2):203-18. PubMed ID: 17660022
[TBL] [Abstract][Full Text] [Related]
17. Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
Yılmaz S; Özçakar ZB; Taktak A; Kiremitçi S; Ensari A; Dinçaslan H; Yalçınkaya F
Pediatr Nephrol; 2016 Jun; 31(6):1029-32. PubMed ID: 26928310
[TBL] [Abstract][Full Text] [Related]
18. [Angiogenesis inhibitors: mechanism of action and nephrotoxicity].
Clou E; Luque Y
Nephrol Ther; 2022 Feb; 18(1):1-6. PubMed ID: 34838486
[TBL] [Abstract][Full Text] [Related]
19. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma.
Hirsch L; Flippot R; Escudier B; Albiges L
Drugs; 2020 Aug; 80(12):1169-1181. PubMed ID: 32601914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]